Pulmonary Arterial Hypertension - Pipeline Review, H2 2016

Pulmonary Arterial Hypertension - Pipeline Review, H2 2016


  • Products Id :- GMDHC8450IDB
  • |
  • Pages: 214
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Pulmonary Arterial Hypertension - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Pulmonary Arterial Hypertension - Pipeline Review, H2 2016', provides an overview of the Pulmonary Arterial Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension

- The report reviews pipeline therapeutics for Pulmonary Arterial Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Pulmonary Arterial Hypertension therapeutics and enlists all their major and minor projects

- The report assesses Pulmonary Arterial Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Pulmonary Arterial Hypertension

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Pulmonary Arterial Hypertension Overview 9

Therapeutics Development 10

Pipeline Products for Pulmonary Arterial Hypertension - Overview 10

Pipeline Products for Pulmonary Arterial Hypertension - Comparative Analysis 11

Pulmonary Arterial Hypertension - Therapeutics under Development by Companies 12

Pulmonary Arterial Hypertension - Therapeutics under Investigation by Universities/Institutes 15

Pulmonary Arterial Hypertension - Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Pulmonary Arterial Hypertension - Products under Development by Companies 19

Pulmonary Arterial Hypertension - Products under Investigation by Universities/Institutes 23

Pulmonary Arterial Hypertension - Companies Involved in Therapeutics Development 24

Actelion Ltd 24

APT Therapeutics, Inc. 25

Arena Pharmaceuticals, Inc. 26

Ascendis Pharma A/S 27

AVEO Pharmaceuticals, Inc. 28

Bial - Portela & Ca, S.A. 29

Celsion Corporation 30

Celtaxsys, Inc. 31

Chugai Pharmaceutical Co., Ltd. 32

Complexa, Inc. 33

Eli Lilly and Company 34

Galectin Therapeutics, Inc. 35

Gilead Sciences, Inc. 36

Hanmi Pharmaceuticals, Co. Ltd. 37

HitGen LTD 38

Insmed Incorporated 39

INVENT Pharmaceuticals, Inc. 40

Johnson & Johnson 41

Kowa Company, Ltd. 42

Mast Therapeutics, Inc. 43

Mezzion Pharma Co. Ltd. 44

miRagen Therapeutics, Inc. 45

Morphogen-IX Limited 46

Nippon Kayaku Co., Ltd. 47

Nippon Shinyaku Co., Ltd. 48

Novartis AG 49

Peloton Therapeutics, Inc. 50

PhaseBio Pharmaceuticals, Inc. 51

Pluristem Therapeutics Inc. 52

Proteo, Inc. 53

Pulmokine, Inc. 54

Reata Pharmaceuticals, Inc. 55

Respira Therapeutics, Inc. 56

Reviva Pharmaceuticals Inc. 57

Selten Pharma, Inc 58

Silence Therapeutics Plc 59

SteadyMed Therapeutics, Inc. 60

Suda Ltd 61

Toray Industries, Inc. 62

Pulmonary Arterial Hypertension - Therapeutics Assessment 63

Assessment by Monotherapy Products 63

Assessment by Target 64

Assessment by Mechanism of Action 68

Assessment by Route of Administration 72

Assessment by Molecule Type 74

Drug Profiles 76

acebilustat - Drug Profile 76

Antibody for Pulmonary Arterial Hypertension - Drug Profile 79

Antisense Oligonucleotide to Inhibit miR-145 for Pulmonary Arterial Hypertension - Drug Profile 80

APT-602 - Drug Profile 81

AV-353 - Drug Profile 82

bardoxolone methyl - Drug Profile 83

beraprost sodium ER - Drug Profile 87

beraprost sodium SR - Drug Profile 88

BIA-51058 - Drug Profile 89

BMP-10 - Drug Profile 90

BMP-9 - Drug Profile 91

CTX-3397 - Drug Profile 92

CXA-10 - Drug Profile 93

Drugs to Inhibit Notch3 for Pulmonary Arterial Hypertension - Drug Profile 95

GMA-301 - Drug Profile 96

GMCT-01 - Drug Profile 97

GRMD-02 - Drug Profile 101

HGP-1207 - Drug Profile 112

INS-1009 - Drug Profile 113

INV-240 - Drug Profile 115

JNJ-26993135 - Drug Profile 116

KAR-5585 - Drug Profile 117

macitentan - Drug Profile 118

MFC-1040 - Drug Profile 123

MFC-2040 - Drug Profile 124

Oligonucleotide to Inhibit Endothelin-1 for CVS, Oncology and Respiratory Diseases - Drug Profile 125

Oligonucleotide to Inhibit MicroRNA-145 for Pulmonary Arterial Hypertension - Drug Profile 126

PB-1046 - Drug Profile 127

PB-1120 - Drug Profile 129

PF-543 - Drug Profile 130

pitavastatin NP - Drug Profile 131

PK-10453 - Drug Profile 132

PK-10571 - Drug Profile 133

PLX-PAD - Drug Profile 134

PT-2977 - Drug Profile 142

QCC-374 - Drug Profile 143

R-190 - Drug Profile 144

ralinepag - Drug Profile 146

RP-5063 - Drug Profile 148

RT-234 - Drug Profile 150

selexipag - Drug Profile 151

selonsertib - Drug Profile 155

sirolimus albumin-bound - Drug Profile 156

Small Molecule to Inhibit ROCK-2 for Cardiovascular, Ophthalmology and Oncology - Drug Profile 158

Small Molecules to Activate ACE2 for Pulmonary Arterial Hypertension - Drug Profile 159

Small Molecules to Antagonize 5-HT1B for Pulmonary Arterial Hypertension - Drug Profile 160

Small Molecules to Antagonize PDGFR for Pulmonary Arterial Hypertension - Drug Profile 161

Small Molecules to Inhibit Soluble Epoxide Hydrolase for Pulmonary Arterial Hypertension - Drug Profile 162

sodium nitrite - Drug Profile 163

SPI-054 - Drug Profile 166

SPI-183 - Drug Profile 167

SUD-004 - Drug Profile 168

Synthetic Peptide to Antagonize Urotensin-II Receptor for Pulmonary Arterial Hypertension - Drug Profile 169

tacrolimus - Drug Profile 170

tadalafil - Drug Profile 171

tiprelestat - Drug Profile 173

tocilizumab - Drug Profile 177

TR-422 - Drug Profile 185

treprostinil - Drug Profile 186

treprostinil diolamine - Drug Profile 187

ubenimex - Drug Profile 189

udenafil - Drug Profile 191

Pulmonary Arterial Hypertension - Dormant Projects 194

Pulmonary Arterial Hypertension - Discontinued Products 198

Pulmonary Arterial Hypertension - Product Development Milestones 199

Featured News & Press Releases 199

Appendix 209

Methodology 209

Coverage 209

Secondary Research 209

Primary Research 209

Expert Panel Validation 209

Contact Us 209

Disclaimer 210

List of Figures

Number of Products under Development for Pulmonary Arterial Hypertension, H2 2016 14

Number of Products under Development for Pulmonary Arterial Hypertension - Comparative Analysis, H2 2016 15

Number of Products under Development by Companies, H2 2016 16

Number of Products under Investigation by Universities/Institutes, H2 2016 19

Comparative Analysis by Late Stage Development, H2 2016 20

Comparative Analysis by Clinical Stage Development, H2 2016 21

Comparative Analysis by Early Stage Products, H2 2016 22

Assessment by Monotherapy Products, H2 2016 67

Number of Products by Top 10 Targets, H2 2016 68

Number of Products by Stage and Top 10 Targets, H2 2016 68

Number of Products by Top 10 Mechanism of Actions, H2 2016 72

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 72

Number of Products by Routes of Administration, H2 2016 76

Number of Products by Stage and Routes of Administration, H2 2016 76

Number of Products by Top 10 Molecule Types, H2 2016 78

Number of Products by Stage and Top 10 Molecule Types, H2 2016 78

List of Tables

Number of Products under Development for Pulmonary Arterial Hypertension, H2 2016 14

Number of Products under Development for Pulmonary Arterial Hypertension - Comparative Analysis, H2 2016 15

Number of Products under Development by Companies, H2 2016 16

Number of Products under Development by Companies, H2 2016 (Contd..1) 17

Number of Products under Development by Companies, H2 2016 (Contd..2) 18

Number of Products under Investigation by Universities/Institutes, H2 2016 19

Comparative Analysis by Late Stage Development, H2 2016 20

Comparative Analysis by Clinical Stage Development, H2 2016 21

Comparative Analysis by Early Stage Development, H2 2016 22

Products under Development by Companies, H2 2016 23

Products under Development by Companies, H2 2016 (Contd..1) 24

Products under Development by Companies, H2 2016 (Contd..2) 25

Products under Development by Companies, H2 2016 (Contd..3) 26

Products under Investigation by Universities/Institutes, H2 2016 27

Pulmonary Arterial Hypertension - Pipeline by Actelion Ltd, H2 2016 28

Pulmonary Arterial Hypertension - Pipeline by APT Therapeutics, Inc., H2 2016 29

Pulmonary Arterial Hypertension - Pipeline by Arena Pharmaceuticals, Inc., H2 2016 30

Pulmonary Arterial Hypertension - Pipeline by Ascendis Pharma A/S, H2 2016 31

Pulmonary Arterial Hypertension - Pipeline by AVEO Pharmaceuticals, Inc., H2 2016 32

Pulmonary Arterial Hypertension - Pipeline by Bial - Portela & Ca, S.A., H2 2016 33

Pulmonary Arterial Hypertension - Pipeline by Celsion Corporation, H2 2016 34

Pulmonary Arterial Hypertension - Pipeline by Celtaxsys, Inc., H2 2016 35

Pulmonary Arterial Hypertension - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2016 36

Pulmonary Arterial Hypertension - Pipeline by Complexa, Inc., H2 2016 37

Pulmonary Arterial Hypertension - Pipeline by Eli Lilly and Company, H2 2016 38

Pulmonary Arterial Hypertension - Pipeline by Galectin Therapeutics, Inc., H2 2016 39

Pulmonary Arterial Hypertension - Pipeline by Gilead Sciences, Inc., H2 2016 40

Pulmonary Arterial Hypertension - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 41

Pulmonary Arterial Hypertension - Pipeline by HitGen LTD, H2 2016 42

Pulmonary Arterial Hypertension - Pipeline by Insmed Incorporated, H2 2016 43

Pulmonary Arterial Hypertension - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016 44

Pulmonary Arterial Hypertension - Pipeline by Johnson & Johnson, H2 2016 45

Pulmonary Arterial Hypertension - Pipeline by Kowa Company, Ltd., H2 2016 46

Pulmonary Arterial Hypertension - Pipeline by Mast Therapeutics, Inc., H2 2016 47

Pulmonary Arterial Hypertension - Pipeline by Mezzion Pharma Co. Ltd., H2 2016 48

Pulmonary Arterial Hypertension - Pipeline by miRagen Therapeutics, Inc., H2 2016 49

Pulmonary Arterial Hypertension - Pipeline by Morphogen-IX Limited, H2 2016 50

Pulmonary Arterial Hypertension - Pipeline by Nippon Kayaku Co., Ltd., H2 2016 51

Pulmonary Arterial Hypertension - Pipeline by Nippon Shinyaku Co., Ltd., H2 2016 52

Pulmonary Arterial Hypertension - Pipeline by Novartis AG, H2 2016 53

Pulmonary Arterial Hypertension - Pipeline by Peloton Therapeutics, Inc., H2 2016 54

Pulmonary Arterial Hypertension - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2016 55

Pulmonary Arterial Hypertension - Pipeline by Pluristem Therapeutics Inc., H2 2016 56

Pulmonary Arterial Hypertension - Pipeline by Proteo, Inc., H2 2016 57

Pulmonary Arterial Hypertension - Pipeline by Pulmokine, Inc., H2 2016 58

Pulmonary Arterial Hypertension - Pipeline by Reata Pharmaceuticals, Inc., H2 2016 59

Pulmonary Arterial Hypertension - Pipeline by Respira Therapeutics, Inc., H2 2016 60

Pulmonary Arterial Hypertension - Pipeline by Reviva Pharmaceuticals Inc., H2 2016 61

Pulmonary Arterial Hypertension - Pipeline by Selten Pharma, Inc, H2 2016 62

Pulmonary Arterial Hypertension - Pipeline by Silence Therapeutics Plc, H2 2016 63

Pulmonary Arterial Hypertension - Pipeline by SteadyMed Therapeutics, Inc., H2 2016 64

Pulmonary Arterial Hypertension - Pipeline by Suda Ltd, H2 2016 65

Pulmonary Arterial Hypertension - Pipeline by Toray Industries, Inc., H2 2016 66

Assessment by Monotherapy Products, H2 2016 67

Number of Products by Stage and Target, H2 2016 69

Number of Products by Stage and Mechanism of Action, H2 2016 73

Number of Products by Stage and Route of Administration, H2 2016 77

Number of Products by Stage and Molecule Type, H2 2016 79

Pulmonary Arterial Hypertension - Dormant Projects, H2 2016 198

Pulmonary Arterial Hypertension - Dormant Projects (Contd..1), H2 2016 199

Pulmonary Arterial Hypertension - Dormant Projects (Contd..2), H2 2016 200

Pulmonary Arterial Hypertension - Dormant Projects (Contd..3), H2 2016 201

Pulmonary Arterial Hypertension - Discontinued Products, H2 2016 202

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Actelion Ltd

APT Therapeutics, Inc.

Arena Pharmaceuticals, Inc.

Ascendis Pharma A/S

AVEO Pharmaceuticals, Inc.

Bial - Portela & Ca, S.A.

Celsion Corporation

Celtaxsys, Inc.

Chugai Pharmaceutical Co., Ltd.

Complexa, Inc.

Eli Lilly and Company

Galectin Therapeutics, Inc.

Gilead Sciences, Inc.

Hanmi Pharmaceuticals, Co. Ltd.

HitGen LTD

Insmed Incorporated

INVENT Pharmaceuticals, Inc.

Johnson & Johnson

Kowa Company, Ltd.

Mast Therapeutics, Inc.

Mezzion Pharma Co. Ltd.

miRagen Therapeutics, Inc.

Morphogen-IX Limited

Nippon Kayaku Co., Ltd.

Nippon Shinyaku Co., Ltd.

Novartis AG

Peloton Therapeutics, Inc.

PhaseBio Pharmaceuticals, Inc.

Pluristem Therapeutics Inc.

Proteo, Inc.

Pulmokine, Inc.

Reata Pharmaceuticals, Inc.

Respira Therapeutics, Inc.

Reviva Pharmaceuticals Inc.

Selten Pharma, Inc

Silence Therapeutics Plc

SteadyMed Therapeutics, Inc.

Suda Ltd

Toray Industries, Inc.

Pulmonary Arterial Hypertension Therapeutic Products under Development, Key Players in Pulmonary Arterial Hypertension Therapeutics, Pulmonary Arterial Hypertension Pipeline Overview, Pulmonary Arterial Hypertension Pipeline, Pulmonary Arterial Hypertension Pipeline Assessment

select a license

Single User License
USD 2000 INR 129160
Site License
USD 4000 INR 258320
Corporate User License
USD 6000 INR 387480

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com